Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01301391 · ClinicalTrials.gov registry record · Phase 2
Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
A Phase 2 study, sponsored by Tiziana Life Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01301391 is a Phase 2 study that was terminated before completion, run by Tiziana Life Sciences. The registered enrollment target is 30 participants.
The verdict
NCT01301391, a Phase 2 study, was terminated before completion, sponsored by Tiziana Life Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The intent of the study is to assess the antitumor activity of PHA-848125AC in patients with recurrent or metastatic, unresectable malignant thymoma previously treated with multiple lines of chemotherapy.
Interventions
- DRUG Milciclib Maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-02-02 |
| Est. Completion | 2018-12-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01301391
The ClinicalTrials.gov registry entry for NCT01301391 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tiziana Life Sciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Milciclib Maleate is the first listed.
NCT01301391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01301391 about?
NCT01301391 is a clinical study titled "Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy". The intent of the study is to assess the antitumor activity of PHA-848125AC in patients with recurrent or metastatic, unresectable malignant thymoma previously treated with multiple lines of chemotherapy.
What is the current status of trial NCT01301391?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2011-02-02. Estimated completion is 2018-12-17.
What interventions are being tested in trial NCT01301391?
The interventions under investigation include: Milciclib Maleate (DRUG).
Who is sponsoring clinical trial NCT01301391?
This trial is sponsored by Tiziana Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.